{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04664829",
      "OrgStudyIdInfo": {
        "OrgStudyId": "BEXMET"
      },
      "Organization": {
        "OrgFullName": "National Cancer Centre, Singapore",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC",
      "OfficialTitle": "Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like Phenotype"
    },
    "StatusModule": {
      "StatusVerifiedDate": "December 2020",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 1, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 30, 2023",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 30, 2023",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "November 9, 2020",
      "StudyFirstSubmitQCDate": "December 7, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 11, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "December 7, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "December 11, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "National Cancer Centre, Singapore",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "National Medical Research Council (NMRC), Singapore",
            "CollaboratorClass": "OTHER_GOV"
          }
        ]
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Triple-negative breast cancer (TNBC) is biologically aggressive and has limited systemic treatment options, often compounded by treatment resistance.\n\nCell state transitions, e.g. epithelial-to-mesenchymal transition (EMT) govern cancer cell behaviour.\n\nThe investigators hypothesize that by inducing change in cell state change, TNBC cells that have manifested taxane-resistance will be more sensitized to subsequent chemotherapy."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Metastatic Triple-Negative Breast Carcinoma"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Bexarotene"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "12",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Bexarotene and Capecitabine",
            "ArmGroupType": "Experimental",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Bexarotene",
                "Drug: Capecitabine"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Bexarotene",
            "InterventionDescription": "Administered orally once a day. Starting dosage: 200mg/m^2",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Bexarotene and Capecitabine"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Targretin"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Capecitabine",
            "InterventionDescription": "Administered orally twice a day. Dosage: 1000mg/m^2",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Bexarotene and Capecitabine"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Xeloda"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Tumour transcriptome by RNA sequencing",
            "PrimaryOutcomeDescription": "To characterize the changes in tumour transcriptome upon treatment",
            "PrimaryOutcomeTimeFrame": "From time of first biopsy before the start of treatment, to disease progression, up to 2 years"
          },
          {
            "PrimaryOutcomeMeasure": "Tumour protein profile by multiplex immunohistochemistry",
            "PrimaryOutcomeDescription": "To characterize the changes in tumour protein profile upon treatment",
            "PrimaryOutcomeTimeFrame": "From time of first biopsy before the start of study treatment, to disease progression, up to 2 years"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Incidences of treatment related adverse events",
            "SecondaryOutcomeTimeFrame": "From time of start of study treatment, to 28 days after last dose of study treatment, up to 2 years"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatients with histologically or cytologically proven metastatic TNBC\nPatients whose TNBC has progressed after prior taxane therapy in the metastatic setting, and have not received Capecitabine or 5-fluorouracil\nFemales aged 21 years and older\nECOG performance status 0 or 1\nLife expectancy greater than three months\nPatients have normal organ and marrow function\nSite(s) of disease amenable to serial bedside biopsies before, during and after study treatment\n\nExclusion Criteria:\n\nPrevious palliative radiotherapy to potentially biopsy-able lesion\nActive symptomatic central nervous system (CNS) metastases\nSpinal cord compression not definitively treated with surgery and/or radiation\nUncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures",
      "HealthyVolunteers": "No",
      "Gender": "Female",
      "GenderBased": "Yes",
      "MinimumAge": "21 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Elaine Lim, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "6436 8000",
            "CentralContactEMail": "elaine.lim.hsuen@singhealth.com.sg"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Elaine Lim, MD",
            "OverallOfficialAffiliation": "National Cancer Centre, Singapore",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "National Cancer Center Singapore",
            "LocationStatus": "Recruiting",
            "LocationCity": "Singapore",
            "LocationZip": "169690",
            "LocationCountry": "Singapore"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 21, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000001943",
            "ConditionMeshTerm": "Breast Neoplasms"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000001941",
            "ConditionAncestorTerm": "Breast Diseases"
          },
          {
            "ConditionAncestorId": "D000012871",
            "ConditionAncestorTerm": "Skin Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M4686",
            "ConditionBrowseLeafName": "Carcinoma",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4372",
            "ConditionBrowseLeafName": "Breast Neoplasms",
            "ConditionBrowseLeafAsFound": "Breast Carcinoma",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6532",
            "ConditionBrowseLeafName": "Disease Susceptibility",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4370",
            "ConditionBrowseLeafName": "Breast Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14826",
            "ConditionBrowseLeafName": "Skin Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000069287",
            "InterventionMeshTerm": "Capecitabine"
          },
          {
            "InterventionMeshId": "D000077610",
            "InterventionMeshTerm": "Bexarotene"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000000964",
            "InterventionAncestorTerm": "Antimetabolites, Antineoplastic"
          },
          {
            "InterventionAncestorId": "D000000963",
            "InterventionAncestorTerm": "Antimetabolites"
          },
          {
            "InterventionAncestorId": "D000045504",
            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
          },
          {
            "InterventionAncestorId": "D000000970",
            "InterventionAncestorTerm": "Antineoplastic Agents"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M377",
            "InterventionBrowseLeafName": "Capecitabine",
            "InterventionBrowseLeafAsFound": "Saline",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M147727",
            "InterventionBrowseLeafName": "Taxane",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M1866",
            "InterventionBrowseLeafName": "Bexarotene",
            "InterventionBrowseLeafAsFound": "Waking",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M3433",
            "InterventionBrowseLeafName": "Antimetabolites",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}